Overall, the RP phage‐based nanovaccine developed in this work demonstrated a strong anti‐tumor CD8+ T cell response, with uniform nanoparticle size and high stability, allowing for single‐step assembly at a potentially low production cost. The gene discussed is CD8A; the disease is neoplasm.